07:41 AM EDT, 10/11/2024 (MT Newswires) -- Sagimet Biosciences ( SGMT ) said Friday that its experimental drug, denifanstat, used to treat certain metabolic-dysfunction-associated steatohepatitis patients, met its primary and secondary endpoints in a phase 2b study.

The study showed that patients treated with the denifanstat showed statistically significant and clinically meaningful improvements in disease activity, MASH resolution, and fibrosis compared to placebo.

The company said it plans to start its phase 3 study of the drug this year.

Shares of the company rose more than 3% in premarket activity.

Price: 4.2900, Change: +0.15, Percent Change: +3.62